参考文献/References:
[1] WANG T J C, MEHTA M P. Low-grade glioma radiotherapy treatment and trials[J]. Neurosurgery Clinics of North America, 2019, 30(1): 111-118.
[2] 秦君翔, 黄锦峰, 袁学刚, 等.miR-124 靶向调控CMTM6 增强CIK 对胶质瘤细胞杀伤效应机制研究[J].现代检验医学杂志, 2023, 38(1): 94-99. QIN Junxiang, HUANG Jinfeng, YUAN Xuegang,et al. Study on the mechanism of miR-124 targeted regulating of CMTM6 to enhance the cytotoxic effect of CIK on glioma cells[J]. Journal of Modern Laboratory Medicine, 2023, 38(1): 94-99.
[3] MATTIROLI F, PENENGO L. Histone ubiquitination:an integrative signaling platform in genome stability[J].Trends in Genetics, 2021, 37(6): 566-581.
[4] YANG Cong, DING Hongyu, YANG Yang, et al. BAP1 regulates AMPK-mTOR signalling pathway through deubiquitinating and stabilizing tumour-suppressor LKB1[J]. Biochemical and Biophysical Research Communications, 2020, 529(4): 1025-1032.
[5] TSAI Sumei, CHU Kuochang, JIANG Yunjin. Newly identified Gon4l/Udu-interacting proteins implicate novel functions[J]. Scientific Reports, 2020, 10(1):14213.
[6] 刘伶, 邹世芳, 巩亮, 等. 血浆外泌体LncRNABLACAT1 和E-cadherin mRNA 表达水平对乳腺癌早期诊断的价值研究[J].现代检验医学杂志, 2022,37(5): 70-75. LIU Ling, ZOU Shifang, GONG Liang, et al. Value of plasma exosomes LncRNA BLACAT1 and E-cadherin mRNA expression in early diagnosis of breast cancer[J].Journal of Modern Laboratory Medicine, 2022, 37(5):70-75.
[7] CAMPAGNE A, LEE M K, ZIELINSKI D, et al. BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation[J]. Nature Communications, 2019, 10(1): 348.
[8] OKONSKA A, FELLEY-BOSCO E. BAP1 missense mutations in cancer: friend or foe?[J]. Trends in Cancer,2019, 5(11): 659-662.
[9] 吴琼, 郑志存.UBE2T 对肝癌细胞增殖、克隆形成及细胞周期的影响及机制研究[J].现代检验医学杂志, 2022, 37(2): 115-120, 125. WU Qiong, ZHENG Zhicun. Effects of UBE2T on proliferation, clone formation and cell cycle of hepatocellular carcinoma cells and its molecular mechanism[J]. Journal of Modern Laboratory Medicine,2022, 37(2): 115-120, 125.
[10] 国家卫生健康委员会医政医管局, 中国抗癌协会脑胶质瘤专业委员会, 中国医师协会脑胶质瘤专业委员会. 脑胶质瘤诊疗指南(2022 版)[J]. 中华神经外科杂志, 2022, 38(8): 757-777. Commission of the People’s Republic of China,Medical Administration and Management Bureau,Committee of of China Anti-Cancer Association,Committee of Glioma of Chinese Medical Doctor Association. Guideline for the diagnosis and treatment of glioma (2022 edition)[J]. Chinese Journal of Neurosurgery, 2022, 38(8): 757-777.
[11] WANG L M, ENGLANDER Z K, MILLER M L, et al. Malignant glioma[J]. Advances in Experimental Medicine and Biology, 2023, 1405: 1-30.
[12] 王金湖, 鞠少卿, 王惠民.抑癌基因PTEN 与人类肿瘤的研究进展[J].现代检验医学杂志, 2003, 18 (1):57-59. WANG Jinhu, JU Shaoqing, WANG Huimin. Progress in research on tumor suppressor gene PTEN and human tumor[J]. Journal of Modern Laboratory Medicine,2003, 18(1): 57-59.
[13] LI Jinjian, MENG Qing, ZHOU Xuehui, et al. Gospel of malignant glioma: oncolytic virus therapy[J]. Gene,2022, 818: 146217.
[14] ZHANG Nan, ZHANG Hao, WANG Zeyu, et al. Immune infiltrating cells-derived risk signature based on large-scale analysis defines immune landscape and predicts immunotherapy responses in glioma tumor microenvironment[J]. Frontiers in Immunology, 2021,12: 691811.
[15] WANG Guanyu, WANG Jinpeng, NIU Chaoshi, et al. Neutrophils: new critical regulators of glioma[J].Frontiers in Immunology, 2022, 13: 927233.
[16] DELGADO-L?PEZ P D, CORRALES-GARC?A E M, MARTINO J, et al. Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies[J]. Clinical & Translational Oncology, 2017, 19(8): 931-944.
[17] LI Yuanyuan. Modern epigenetics methods in biological research[J]. Methods, 2021, 187: 104-113.
[18] VILLANUEVA L, ?LVAREZ-ERRICO D, ESTELLER M. The contribution of epigenetics to cancer immunotherapy[ J]. Trends in Immunology, 2020, 41(8): 676-691.
[19] YADAV P, SUBBARAYALU P, MEDINA D, et al. M6A RNA methylation regulates histone ubiquitination to support cancer growth and progression[J]. Cancer Research, 2022, 82(10): 1872-1889.
[20] LI Jiabin, LIANG Jun, TIAN Changlin. Chemical synthesis of di-ubiquitin modified histones for further biochemical studies[J]. Methods in Enzymology, 2020,639: 263-287.
[21] ABDEL-RAHMAN M H, SAMPLE K M, PILARSKI R, et al. Whole exome sequencing identifies candidate genes associated with hereditary predisposition to uveal melanoma[J]. Ophthalmology, 2020, 127(5): 668-678.
[22] HU Z I, MIETTINEN M, QUEZADO M, et al. Meningiomas in patients with malignant pleural mesothelioma harboring germline BAP1 mutations[J].Journal of Thoracic Oncology, 2022, 17(3): 461-466.
[23] DONATI M, MARTINEK P, STEINER P, et al. Novel insights into the BAP1-inactivated melanocytic tumor[J]. Modern Pathology, 2022, 35(5): 664-675.
[24] JAGER M J, SHIELDS C L, CEBULLA C M, et al. Uveal melanoma[J]. Nature Reviews Disease Primers,2020, 6(1): 24.
[25] MASCLEF L, AHMED O, ESTAVOYER B, et al. Roles and mechanisms of BAP1 deubiquitinase in tumor suppression[J]. Cell Death and Differentiation,2021, 28(2): 606-625.
[26] BORU G, GROSEL T W, PILARSKI R, et al. Germline large deletion of BAP1 and decreased expression in non-tumor choroid in uveal melanoma patients with high risk for inherited cancer[J]. Genes Chromosomes & Cancer, 2019, 58(9): 650-656.
[27] LOUIE B H, KURZROCK R. BAP1: not just a BRCA1-associated protein[J]. Cancer Treatment Reviews, 2020, 90: 102091.